Checkpoint Inhibitors Competitive Landscape 2025: Tracking 60+ Immuno-Oncology Agents Reshaping the Cancer Therapeutics Market | DelveInsight

DelveInsight's "Checkpoint Inhibitors - Competitive Landscape, 2025" provides an in-depth analysis of the rapidly evolving immune checkpoint inhibitor (ICI) space, profiling 100+ companies and 150+ drug candidates across various stages of clinical development. As ICIs continue to redefine cancer care, this report explores the crowded and dynamic field of PD-1, PD-L1, CTLA-4, LAG-3, TIGIT, and novel checkpoint modulators.

The report covers a detailed assessment by product type, target class, line of therapy, combination strategies, tumor types, and mechanism of action. It further segments the competitive pipeline by development stage (discovery to Phase III), route of administration (IV, subcutaneous, oral), and molecule type (monoclonal antibodies, fusion proteins, bispecifics, small molecules).

Key players such as Merck & Co., Bristol Myers Squibb, Roche, AstraZeneca, BeiGene, Novartis, Gilead Sciences, and innovative biotech firms like Agenus, I-Mab, and ALX Oncology are investing heavily in combination regimens, biomarker-driven approaches, and next-generation checkpoint targets to overcome resistance and expand indications.

As the checkpoint inhibitor market matures, competition is shifting from first-line monotherapy to differentiated combinations, tumor-agnostic approvals, and novel immune modulators. The report also highlights competitive discontinuations, licensing deals, regional trends, and emerging players aiming to challenge existing market leaders.

Whether you're a stakeholder in immuno-oncology or an investor tracking future market disruptors, DelveInsight's competitive intelligence report offers a robust framework to analyze strategic movements, forecast market shifts, and identify partnering opportunities in the checkpoint inhibitor space.

Interested in learning more about the current treatment landscape and the key drivers shaping the checkpoint inhibitors pipeline? Click here: https://www.delveinsight.com/report-store/checkpoint-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Checkpoint Inhibitors Competitive Landscape Report
• DelveInsight's checkpoint inhibitors competitive analysis depicts a strong space with 50+ active players working to develop 60+ drugs for checkpoint inhibitors treatment.
• The leading checkpoint inhibitors companies include CanBas, Boundless Bio, Sumitomo Pharma America, Pharos I&BT, Virion Therapeutics, OncoC4, Transcode Therapeutics, Inc., and others are evaluating their lead assets to improve the checkpoint inhibitors treatment landscape.
• Key checkpoint inhibitors pipeline therapies in various stages of development include TTX-siPDL1, ONC-841, BBI-355, and others.
• In February 2025, Genome & Company signed a global license agreement with Ellipses Pharma for GENA-104, a novel targeted immuno-oncology drug. Ellipses has agreed to in-license global rights to 'GENA-104', a first-in-class immuno-oncology monoclonal antibody that targets CNTN4, a recently discovered checkpoint protein that is highly expressed in a wide range of tumour types. GENA-104 is a new immune checkpoint inhibitor targeting CNTN4.
• In November 2024, Helix BioPharma Corp. announced that it had entered into an asset purchase agreement with Laevoroc Immunology AG. As a result of the Transaction, Helix acquired the intellectual property, inventory, assigned agreements, and rights to LR 09, an oral immune checkpoint inhibitor in preclinical development for patients relapsing with leukemia after the intensive journey of allogeneic stem cell transplantation (SCT).
• In August 2024, OncoC4, Inc. announced the first patient has been dosed in the first-in-human Phase I ONC-841-002 trial (NCT06352359) evaluating ONC-841, a potential first-in-class SIGLEC10 blocking antibody for the treatment of solid tumors.
• In April 2024, OncoC4, Inc. announced that the FDA cleared the investigational new drug ("IND") application for ONC-841, a potential first-in-class SIGLEC 10 blocking antibody for the treatment of solid tumors.

Request a sample and discover the recent breakthroughs happening in the checkpoint inhibitors competitive landscape at https://www.delveinsight.com/report-store/checkpoint-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Checkpoint Inhibitors Overview
Immune checkpoints are natural regulators that prevent the immune system from attacking healthy tissues. Cancer cells often exploit these checkpoints-like PD-1, PD-L1, and CTLA-4-to "turn off" T cells and evade detection.

Immune checkpoint inhibitors (ICIs) are immunotherapy drugs designed to block these interactions, effectively lifting the immune system's brakes and enabling T cells to recognize and destroy cancer cells. These therapies have become a cornerstone in the treatment of cancers such as melanoma, lung, bladder, kidney, and head and neck cancers.

ICIs may be used alone or in combination and have significantly improved survival outcomes. However, they can trigger immune-related side effects (irAEs), such as inflammation in the lungs, liver, or intestines. Interestingly, the presence of irAEs often correlates with stronger therapeutic responses, particularly with PD-L1 blockade.

Find out more about checkpoint inhibitors medication at https://www.delveinsight.com/report-store/checkpoint-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Checkpoint Inhibitors: Company and Product Profiles (Marketed Therapies)
1. Company Overview: Bristol Myers Squibb/ Ono Pharmaceuticals
Bristol Myers Squibb (BMS), based in New York, is a global biopharma leader focused on oncology, immunology, cardiovascular, and fibrosis. With a strong pipeline and a commitment to innovation and sustainability, BMS collaborates globally to improve health outcomes. Ono Pharmaceutical, headquartered in Osaka, Japan, specializes in oncology and immunology. It played a key role in the development of checkpoint inhibitors and partners internationally to bring new therapies to market.

ProductL OPDIVO (Nivolumab)
Opdivo is a PD-1 checkpoint inhibitor that reactivates T cells to target cancer. Approved in 65+ countries, it is used across various tumors and has treated over 35,000 patients. It was the first PD-1 inhibitor approved globally (2014) and is also part of the first approved I-O combo (Opdivo + Yervoy) for metastatic melanoma.

2. Company Overview: Genentech
Genentech, a pioneer in biotech and a Roche company since 2009, is based in South San Francisco. It focuses on oncology, immunology, and neuroscience, and is known for biologics like Herceptin, Avastin, and Rituxan. It remains a major innovation hub with a robust R&D pipeline.

Product: TECENTRIQ (Atezolizumab)
Tecentriq is a PD-L1 inhibitor that restores the immune response against tumors. Approved for NSCLC, TNBC, HCC, and urothelial carcinoma, it can be used alone or with other therapies. Administered via IV, it plays a central role in cancer immunotherapy with a manageable safety profile.

Checkpoint Inhibitors: Company and Product Profiles (Pipeline Therapies)
1. Company Overview: OncoC4
OncoC4 is a U.S.-based clinical-stage biopharma company developing next-gen immunotherapies. Its core focus is on modulating immune checkpoints to boost anti-tumor responses. Through innovative science and strategic collaborations, OncoC4 is advancing treatments that address unmet needs in cancer care.

Product: ONC-841
ONC-841 is the first clinical-stage SIGLEC10 antagonist, targeting immune evasion mechanisms in solid tumors. It blocks the SIGLEC10-CD24 interaction, reactivating immune cells like NK cells, macrophages, and T cells. Preclinical data support its role in enhancing phagocytosis, T-cell activity, and ADCC. ONC-841 is currently in Phase I trials for advanced solid tumors.

2. Company Overview: Kyowa Kirin
Boundless Bio, based in San Diego, is pioneering therapies for oncogene-amplified tumors driven by extrachromosomal DNA (ecDNA). Its ecDNA-directed therapeutics (ecDTx) aim to address a critical gap in cancer treatment by targeting replication stress vulnerabilities in tumor cells.

Product: BBI-355
BBI-355 is a selective oral CHK1 inhibitor being tested in the Phase 1/2 POTENTIATE trial (NCT05827614). It targets replication stress in ecDNA-amplified cancer cells, causing cell death while sparing healthy cells. It's the first CHK1 inhibitor developed specifically for ecDNA-driven oncogene amplification.

Discover how emerging checkpoint inhibitors therapies stack up against current treatments in the evolving market landscape: https://www.delveinsight.com/report-store/checkpoint-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Checkpoint Inhibitors Therapeutics Assessment
Company Analysis
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Scope of the Checkpoint Inhibitors Competitive Landscape Report
• Coverage: Global
• Key Checkpoint inhibitors Companies: Santen Pharmaceuticals, Nicox Ophthalmics, Qlaris Bio, VivaVision Biotech, Theratocular Biotek, Perfuse Therapeutics, Omikron Italia S.r.l., Laboratoires Thea, PolyActiva Pty Ltd, Amydis Inc., and others.
• Key Checkpoint inhibitors Pipeline Therapies: DE-130A, PDP-716, NCX 470, DE-126, PHP-201, Citicoline, TRS01, TC-002, T4032, Bremen, POLAT 001, BTQ-1902, Nyxol, IN-A010, VVN539, and others.

To dive deep into rich insights for drugs used for checkpoint inhibitors treatment, visit: https://www.delveinsight.com/report-store/checkpoint-inhibitors-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Checkpoint inhibitors Overview
4. Analytical & Commercial Assessment
5. Competitive Landscape
6. Marketed Therapies
7. Pipeline Therapies (by development stage)
8. Unmet Needs
9. Market Drivers & Barriers
10. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.